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Purpose: We performed a comparative analysis of the plasma levels of antithrombin 
(AT) III, plasminogen, fibrinogen, and D-dimer among patients with and without clin-
ically localized prostate cancer to investigate the clinical significance of the coagulation 
profile in prostate cancer.
Materials and Methods: A prospective study was performed in which plasma levels of 
AT III, plasminogen, fibrinogen, and D-dimer were assessed in patients before they un-
derwent prostate biopsy. According to the results of the biopsy, the patients were catego-
rized into the cancer group or the control group. Levels of the four coagulation factors 
were then compared between the cancer and control groups. Also, levels of the four coag-
ulation factors were correlated with tumor stage and grade in the cancer group.
Results: The cancer group had significantly lower levels of AT III activity and higher 
plasma D-dimer levels than did the control group (p=0.007 and p=0.018, respectively). 
Within the cancer group, no significant differences were observed in the levels of AT 
III, plasminogen, fibrinogen, or D-dimer between those with a pathological Gleason 
score of ≥7 and otherwise. Regarding pathologic stage of prostate cancer, the subjects 
with organ-confined disease and those with extraprostatic extension of a tumor demon-
strated no significant differences in the preoperative levels of the four coagulation fac-
tors analyzed.
Conclusions: Our results suggest that plasma levels of AT III and D-dimer are altered 
in patients with prostate cancer. Further study is needed to elucidate the underlying 
mechanism and clinical significances of such a phenomenon among patients with clin-
ically localized prostate cancer.
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INTRODUCTION
Abnormalities of the coagulation system have long been 
recognized in cancer patients, in whom the plasma levels 
of several coagulation factors have been observed to be al-
tered [1,2]. Moreover, thromboembolism has been reported 
as being the second most frequent cause of death in cancer 
patients [3]. Even without obvious thrombosis, patients 
with solid tumors commonly present with subclinical pro-
thrombotic or hypercoagulable conditions [4,5]. However, 
it is still unclear whether such abnormalities in coagu-
lation bear any significance in the pathogenesis or pro-
gression of the malignant process. Meanwhile, the extent 
of activation of coagulation and fibrinolysis, as measured 
via plasma levels of antithrombin (AT) III and D-dimer, has 
been reported to correlate with tumor stage, aggressive-
ness, and prognosis in various malignancies, including col-
orectal, breast, ovarian, and lung cancer [6-9].
As for prostate cancer, a growing body of evidence sug-
gests that the components of the coagulation and fi-
brinolysis system are involved in the pathogenesis and pro-
gression of this disease as well. For example, AT, a major 
plasma inhibitor of coagulating proteases, has been re-
ported to be widely expressed in prostate cancer tissue but 
is gradually lost with increasing tumor grade [10]. Also, 
plasma AT levels in prostate cancer patients are observed 
to be increased after radical prostatectomy (RP) [11]. In ad-
dition, D-dimer, a stable end-product of fibrin degradation 
that has been known to be a useful prognostic marker for 
several solid tumors, has also been reported to be sig-Korean J Urol 2010;51:25-29
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TABLE 1. Patient characteristics
Cancer group (n=93) Control group (n=56) p-value
Mean age±SD (years)
Mean BMI±SD (kg/m
2)
Mean PSA±SD (ng/ml)
Mean prostate volume±SD (ml)
Mean antithrombin III±SD (%)
Mean plasminogen±SD (%)
Mean fibrinogen±SD (mg/ml)
Mean D-dimer±SD (μg/ml)
66.1±7.3
24.2±2.6
12.5±15.7
44.3±25.2
88.5±12.0
92.5±34.9
309.3±83.4
0.53±0.48
63.1±9.4
24.78±2.2
4.9±1.8
47.9±18.6
94.1±11.2
96.5±16.2
309.6±60.3
0.36±0.31
　0.120
　0.245
＜0.001
　0.359
　0.007
　0.447
　0.985
　0.018
SD: standard deviation, BMI: body mass index, PSA: prostate-specific antigen
nificantly increased in prostate cancer patients compared 
with healthy controls [12]. Meanwhile, compared with oth-
er cancers, a paucity of data exists regarding the clinical 
significance of these coagulation factors regarding clin-
ically localized prostate cancer. Thus, we performed a com-
parative analysis of the plasma levels of AT III, plasmi-
nogen, fibrinogen, and D-dimer among patients with and 
without clinically localized prostate cancer to elucidate the 
clinical significance of the coagulation profile in prostate 
cancer.
MATERIALS AND METHODS
From July to December 2008, a prospective study was per-
formed at our institution upon approval from our institu-
tional review board (IRB no. B-0803-055-004) in which 
blood samples were collected from men before they under-
went transrectal ultrasound (TRUS) guided multi-core bi-
opsy of the prostate under the suspicion of prostate cancer. 
Among the 369 patients who gave written informed con-
sent to participate in the study, 129 (34.9%) were diagnosed 
with prostate cancer from the biopsy. Of those who were not 
diagnosed as having prostate cancer, 56 men with an initial 
prostate-specific antigen (PSA) level of ＜10 ng/ml were se-
lected and designated as the control group. Of those with 
prostate cancer, 93 who underwent RP were selected and 
included in the cancer group.
Blood sampling was performed before the scheduled 
prostate biopsy in each subject. Blood from a clean ven-
ipuncture was mixed with 0.129 mol/l trisodium citrate 
(Merck) containing 0.21 mol/l HEPES (Sigma) in cold plas-
tic tubes. The blood was immediately spun at 2,000 g for 
15 minutes in a refrigerated centrifuge. All coagulation pa-
rameters were measured within 2 hours of sample 
collection. The following assays were performed: fibri-
nogen (Clauss) with international standards from the 
National Institute for Biological Standards and Control 
(NIBSC), Hempstead, England; D-dimer via ELISA 
(Diagnostic Stago, France); ATIII activity via chromogenic 
substrate assay (S2238) with plasma standard calibration 
made against international standards (Chromogenix, 
Sweden); and plasminogen activity via hydrolysis of a chro-
mogenic substrate (Coamatic, Chromogenix Instr. Lab. 
SpA, Milano, Italy).
Various clinicopathological data were also assessed in 
the aforementioned subjects of the cancer and control 
groups: patient age at the time of surgery, body mass index 
(BMI), preoperative PSA level, prostate volume assessed 
via preoperative TRUS exam, pathologic Gleason grade, 
pathologic stage, and surgical margin status. First, we 
compared the coagulation profiles of the cancer and control 
groups. Also, the coagulation profiles of the cancer group 
were correlated with cancer-related profiles of the 
patients.
The SPSS software package version 15.0 (Statistical 
Package for Social Sciences
TM, Chicago, USA) was used for 
statistical analysis. The profiles of the cancer and control 
groups were compared via independent-sample T tests. 
Comparison of continuous variables in different subgroups 
was performed by Mann-Whitney U-test or Kruskal- 
Wallis test. Relationships between categorical variables 
were compared by using chi-square test. A p-value less 
than 0.05 was considered statistically significant.
RESULTS
The characteristics of the subjects are listed in Table 1. As 
can be seen, the cancer and control groups did not differ sig-
nificantly regarding age, BMI, or prostate volume meas-
ured via TRUS. The mean serum PSA levels of the cancer 
and control groups were 12.5±15.7 ng/ml and 4.9±1.8 
ng/ml, respectively, demonstrating a significant difference 
(p＜0.001). As for the coagulation profiles analyzed, the 
two groups demonstrated no significant differences with 
regard to plasminogen activity (p=0.447) or fibrinogen lev-
el (p=0.985). On the other hand, AT III activity was sig-
nificantly lower and the plasma D-dimer level was sig-
nificantly higher in the cancer group than in the control 
group (p=0.007 and p=0.018, respectively).
Within the cancer group, those with pathological 
Gleason score of ≥7 demonstrated lower preoperative 
ATIII activity than did the other patients, but the differ-
ence only approached significance (p=0.085) (Table 2). 
Concerning the other coagulation-related parameters, the 
subjects with a pathologic Gleason score of ≤6 and those 
with a pathologic Gleason score of ≥7 showed no sig-Korean J Urol 2010;51:25-29
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TABLE 2. Coagulation profiles according to pathologic Gleason score
Pathologic GS≤6
(n=20)
Pathologic GS≥7
(n=57)
p-value
Mean antithrombin III±SD (%)
Mean plasminogen±SD (%)
Mean fibrinogen±SD (mg/ml)
Mean D-dimer±SD (μg/ml)
91.9±14.3
96.2±19.4
303.8±99.2
0.42±0.37
86.4±10.8
89.9±41.7
297.4±61.4
0.50±0.39
0.085
0.547
0.735
0.427
GS: Gleason score, SD: standard deviation
TABLE 3. Coagulation profiles according to pathologic stage of prostate cancer
Organ confined disease
(n=54)
Extraprostatic disease
(n=23)
p-value
Mean antithrombin III±SD (%)
Mean plasminogen±SD (%)
Mean fibrinogen±SD (mg/ml)
Mean D-dimer±SD (μg/ml)
88.6±12.7
88.0±19.8
297.3±79.2
0.47±0.42
86.7±10.5
98.0±56.6
303.1±54.5
0.50±0.31
0.534
0.298
0.749
0.774
SD: standard deviation
nificant differences in preoperative levels of plasminogen 
activity (p=0.547), fibrinogen (p=0.735), or D-dimer (p= 
0.427). When the same analysis was performed by using a 
pathologic Gleason score cutoff of 8, the results were the 
same. With regard to pathologic stage of prostate cancer, 
the subjects with organ-confined disease and those with ex-
traprostatic extension of a tumor confirmed on pathologic 
examination of RP specimens demonstrated no significant 
differences in preoperative levels of AT III (p=0.534), plas-
minogen (p=0.298), fibrinogen (p=0.749), or D-dimer (p= 
0.774) (Table 3).
DISCUSSION
In the current study, we observed that the plasma level of 
AT III was significantly decreased, whereas the D-dimer 
level was significantly increased, in patients with clinically 
localized prostate cancer compared with those without evi-
dence of cancer on prostate biopsy. Such findings imply 
that, regarding prostate cancer, the coagulation system 
may well be associated with carcinogenesis. On the other 
hand, among our subjects with prostate cancer, pre-
operative levels of AT III, plasminogen, fibrinogen, and 
D-dimer had no significant associations with tumor stage 
or grade, which are established prognostic predictors of 
prostate cancer.
Previously, preoperative levels of AT III and D-dimer 
were reported to be useful predictors of prognosis in various 
cancers. Koh et al suggested that plasma levels of AT III 
and D-dimer, together with those of fibrinogen and von 
Willebrand factor, should be used as prognostic markers 
for ovarian cancer [8]. Also, Oya et al reported that an ele-
vated plasma D-dimer level is associated with advanced tu-
mor stage and short survival after curative resection in pa-
tients with colorectal cancer [13]. They observed via multi-
variate analysis that the preoperative plasma D-dimer lev-
el was the third strongest independent prognostic factor, 
exceeded in importance only by lymph node status and car-
cinoembryonic antigen (CEA) level. Similar associations 
have been reported between preoperative plasma D-dimer 
levels and postoperative survival in patients with lung 
cancer. Unsal et al reported that high D-dimer and low AT 
III levels were correlated with advanced tumor stage and 
short survival in patients with lung cancer [9]. Meanwhile, 
Dirix et al observed that plasma D-dimer levels correlated 
with tumor volume, progression rate, and survival in pa-
tients with breast cancer [7]. Thus, evidence has accumu-
lated in the literature to suggest that plasma levels of AT 
III and D-dimer may be significantly associated with 
known prognostic indicators and the survival of patients 
with various malignancies.
As for prostate cancer, some researchers have also pre-
viously reported that AT III and D-dimer may have clinical 
significance. Cao et al found AT to be widely expressed in 
tissues of prostate adenocarcinoma and also observed that 
the expression was gradually lost in tumors of high Gleason 
grade [10]. Beecken et al observed from their series of 40 
consecutive patients with prostate cancer that plasma lev-
els of AT were significantly reduced before RP, only to re-
cover to normal levels within 2 weeks after RP [11]. 
Meanwhile, Caine et al reported that plasma levels of 
D-dimer and fibrinogen were significantly elevated in pros-
tate cancer patients compared with healthy controls [12]. 
These reports can be considered supportive of our finding, 
as we also observed significant differences in the levels of 
AT III and D-dimer between those with and without pros-
tate cancer. Further study is needed to elucidate whether 
the observed levels of AT III and D-dimer are the contrib-
utors or the results of the carcinogenesis regarding pros-
tate cancer. Still, our results suggest that levels of AT III Korean J Urol 2010;51:25-29
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and D-dimer are significantly altered in patients with pros-
tate cancer compared with their healthy counterparts.
Meanwhile, Langer et al reported that the plasma 
D-dimer level was significantly higher in patients with less 
differentiated prostate cancers and also showed a trend of 
being higher in those with locally advanced disease [14]. 
Furthermore, the plasma level of urokinase-type plasmi-
nogen activator (uPA), which transfers plasminogen to 
plasmin, was reported to be associated with features of tu-
mor aggressiveness and progression in prostate cancer. In 
our study, no significant association of the coagulation fac-
tors analyzed with tumor stage or grade was observed 
among the patients with prostate cancer [15]. The pre-
operative level of AT III was lower among those with rela-
tively higher (≥7) pathologic Gleason score, but the differ-
ence only approached significance. Such discrepancy be-
tween our results and other published data may be due to 
the relatively smaller number of subjects included in our 
study. With longer follow-up, the coagulation profiles as-
sessed in our study may demonstrate prognostic sig-
nificance when correlated with parameters such as bio-
chemical recurrence-free or overall survival of cancer 
patients. Thus, relevant investigations would be needed in 
the future regarding our subjects with prostate cancer.
In prostate cancer, chronic disseminated intravascular 
coagulation (DIC) leading to decreases in coagulation fac-
tors, which in turn may elicit thromboembolic complica-
tions, is considered a potential problem [16]. DIC results 
in the production of fibrin, which has been reported to cover 
cancer lesions at the invasion front. Tumors are known to 
actually use fibrin as a support, and fibrin appears to at-
tract new blood vessels. Such a situation demonstrates a 
close interaction between tumors and the hemostatic sys-
tem, eventually leading to tumor growth and invasion. It 
has also been suggested that tumor cells themselves could 
convert fibrinogen to fibrin. D-dimer, a fibrinogen degrada-
tion product, was shown to be associated with tumor pro-
gression in previously reported studies, and an increased 
plasma level of D-dimer may reflect ongoing fibrinogen me-
tabolism within actively remodeling tumor stroma [17]. 
Furthermore, a reduction of AT, which is a major plasma 
inhibitor of coagulating protease, would lead to ex-
aggerated production of fibrin in the case of the activation 
of the coagulation cascade commonly seen in malignancies 
[18]. Moreover, AT has been known to inhibit the angio-
genic activity of tumors [8,19]. Also, AT may act addition-
ally as a local inhibitor of tumor invasion because of its abil-
ity to form complexes with proteases, including plasma kal-
likreins and trypsin. Thus, reductions in the AT level may 
well lead to carcinogenesis, tumor growth, and progression 
in prostate cancer. In our study, we observed a relatively 
lower level of AT III among patients with a higher patho-
logic Gleason score. This finding is supportive of the afore-
mentioned hypothesis of the potential role of AT in prostate 
cancer. Although no prognostic significance of AT III or 
D-dimer was observed in our study, our findings indicate 
that both coagulation factors may well be associated with 
pathogenesis or progression of prostate cancer.
Our study may be limited by the relatively small num-
ber of subjects analyzed. Furthermore, coagulation param-
eters were checked only once in each patient. Also, we fo-
cused on AT III and D-dimer, and plasma levels of various 
other hemostatic factors, such as uPA, were not analyzed. 
We could not assess the effects of factors such as car-
diovascular comorbidities that may also impact the coagu-
lative system. Also, due to the apparent lack of adequate 
follow-up, the significance of coagulation factors regarding 
the disease-specific survival of subjects, which we are plan-
ning to analyze in the future, could not be assessed in the 
current study. Still, we believe that the results of our study 
justify the need for further investigation, basic or clinical, 
on the prognostic significance of various coagulation fac-
tors in prostate cancer.
CONCLUSIONS
Our results suggest that plasma levels of AT III and D-dim-
er are altered in patients with clinically localized prostate 
cancer. Further study is needed to elucidate the underlying 
mechanism and clinical significance of such a phenomenon 
among patients with prostate cancer.
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